Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated:  12/31/1969
Henry Ford Health System
165
mi
from 43215
Detroit, MI
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated: 12/31/1969
Henry Ford Health System
165
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated:  12/31/1969
Hennepin County Medical Center
623
mi
from 43215
Minneapolis, MN
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated: 12/31/1969
Hennepin County Medical Center
623
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated:  12/31/1969
CHU Saint-Pierre University Hospital
4052
mi
from 43215
Brussels,
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated: 12/31/1969
CHU Saint-Pierre University Hospital
4052
mi
from 43215
Brussels,
Click here to add this to my saved trials
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated:  12/31/1969
Tarrant County ID Associates
938
mi
from 43215
Los Angeles, CA
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated: 12/31/1969
Tarrant County ID Associates
938
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated:  12/31/1969
Therafirst Medical Centers
966
mi
from 43215
Fort Lauderdale, FL
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated: 12/31/1969
Therafirst Medical Centers
966
mi
from 43215
Fort Lauderdale, FL
Click here to add this to my saved trials
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated:  12/31/1969
Southampton Healthcare, Inc.
399
mi
from 43215
Saint Louis, MO
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated: 12/31/1969
Southampton Healthcare, Inc.
399
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated:  12/31/1969
AIDS Arms, Inc./Trinity Health & Wellness Center
914
mi
from 43215
Fort Worth, TX
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated: 12/31/1969
AIDS Arms, Inc./Trinity Health & Wellness Center
914
mi
from 43215
Fort Worth, TX
Click here to add this to my saved trials
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated:  12/31/1969
Premier Clinical Research
1779
mi
from 43215
Spokane, WA
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated: 12/31/1969
Premier Clinical Research
1779
mi
from 43215
Spokane, WA
Click here to add this to my saved trials
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated:  12/31/1969
Capital Medical Associates, PC
328
mi
from 43215
Washington,
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated: 12/31/1969
Capital Medical Associates, PC
328
mi
from 43215
Washington,
Click here to add this to my saved trials
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated:  12/31/1969
Dupont Circle Physician's Group
328
mi
from 43215
Washington,
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated: 12/31/1969
Dupont Circle Physician's Group
328
mi
from 43215
Washington,
Click here to add this to my saved trials
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated:  12/31/1969
Medical Faculty Associates
328
mi
from 43215
Washington,
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated: 12/31/1969
Medical Faculty Associates
328
mi
from 43215
Washington,
Click here to add this to my saved trials
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated:  12/31/1969
Whitman Walker Clinic
328
mi
from 43215
Washington,
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated: 12/31/1969
Whitman Walker Clinic
328
mi
from 43215
Washington,
Click here to add this to my saved trials
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated:  12/31/1969
Jersey Shore Medical Center
475
mi
from 43215
Neptune, NJ
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated: 12/31/1969
Jersey Shore Medical Center
475
mi
from 43215
Neptune, NJ
Click here to add this to my saved trials
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center
484
mi
from 43215
Bronx, NY
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center
484
mi
from 43215
Bronx, NY
Click here to add this to my saved trials
Glutathione and Function in HIV Patients
Glutathione and Function in HIV Patients
Status: Enrolling
Updated:  12/31/1969
Baylor Metabolic Research Unit (MRU)
995
mi
from 43215
Houston, TX
Glutathione and Function in HIV Patients
Glutathione and Function in HIV Patients
Status: Enrolling
Updated: 12/31/1969
Baylor Metabolic Research Unit (MRU)
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Status: Enrolling
Updated:  12/31/1969
31788 Alabama CRS
492
mi
from 43215
Birmingham, AL
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Status: Enrolling
Updated: 12/31/1969
31788 Alabama CRS
492
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Status: Enrolling
Updated:  12/31/1969
University of Southern California LA (5048)
1972
mi
from 43215
Los Angeles, CA
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Status: Enrolling
Updated: 12/31/1969
University of Southern California LA (5048)
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Status: Enrolling
Updated:  12/31/1969
University of Florida Jacksonville (5051)
670
mi
from 43215
Jacksonville, FL
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Status: Enrolling
Updated: 12/31/1969
University of Florida Jacksonville (5051)
670
mi
from 43215
Jacksonville, FL
Click here to add this to my saved trials
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Status: Enrolling
Updated:  12/31/1969
Rush University Cook County Hospital Chicago NICHD CRS (5083)
274
mi
from 43215
Chicago, IL
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Status: Enrolling
Updated: 12/31/1969
Rush University Cook County Hospital Chicago NICHD CRS (5083)
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Status: Enrolling
Updated:  12/31/1969
31786 New Jersey Medical School Clinical Research Center CRS
467
mi
from 43215
Newark, NJ
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Status: Enrolling
Updated: 12/31/1969
31786 New Jersey Medical School Clinical Research Center CRS
467
mi
from 43215
Newark, NJ
Click here to add this to my saved trials
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Status: Enrolling
Updated:  12/31/1969
Columbia Physicians and Surgeons CRS (30329)
442
mi
from 43215
New York, NY
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Status: Enrolling
Updated: 12/31/1969
Columbia Physicians and Surgeons CRS (30329)
442
mi
from 43215
New York, NY
Click here to add this to my saved trials
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Status: Enrolling
Updated:  12/31/1969
The Miriam Hospital ACTG CRS (2951)
619
mi
from 43215
Providence, RI
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Status: Enrolling
Updated: 12/31/1969
The Miriam Hospital ACTG CRS (2951)
619
mi
from 43215
Providence, RI
Click here to add this to my saved trials
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Status: Enrolling
Updated:  12/31/1969
Gaborone Prevention/Treatment Trials CRS (12701)
8262
mi
from 43215
Gaborone,
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Status: Enrolling
Updated: 12/31/1969
Gaborone Prevention/Treatment Trials CRS (12701)
8262
mi
from 43215
Gaborone,
Click here to add this to my saved trials
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Status: Enrolling
Updated:  12/31/1969
David Geffen School of Medicine at UCLA NICHD CRS (5112)
1982
mi
from 43215
Los Angeles, CA
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Status: Enrolling
Updated: 12/31/1969
David Geffen School of Medicine at UCLA NICHD CRS (5112)
1982
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Status: Enrolling
Updated:  12/31/1969
Univ. of Colorado Denver NICHD CRS (5052)
1153
mi
from 43215
Aurora, CO
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Status: Enrolling
Updated: 12/31/1969
Univ. of Colorado Denver NICHD CRS (5052)
1153
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Status: Enrolling
Updated:  12/31/1969
Jacobi Medical Center Bronx
482
mi
from 43215
Bronx, NY
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Status: Enrolling
Updated: 12/31/1969
Jacobi Medical Center Bronx
482
mi
from 43215
Bronx, NY
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Alabama CRS
492
mi
from 43215
Birmingham, AL
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Alabama CRS
492
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
University of Southern California CRS
1970
mi
from 43215
Los Angeles, CA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
University of Southern California CRS
1970
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
UCLA CARE Center CRS
1979
mi
from 43215
Los Angeles, CA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
UCLA CARE Center CRS
1979
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
VA West Los Angeles Medical Center CRS
1972
mi
from 43215
Los Angeles, CA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
VA West Los Angeles Medical Center CRS
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Los Angeles LGBT Center CRS
1972
mi
from 43215
Los Angeles, CA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Los Angeles LGBT Center CRS
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Eisenhower Health Center at Rimrock CRS
1888
mi
from 43215
Palm Springs, CA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Eisenhower Health Center at Rimrock CRS
1888
mi
from 43215
Palm Springs, CA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Stanford AIDS Clinical Trials Unit CRS
2102
mi
from 43215
Palo Alto, CA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Stanford AIDS Clinical Trials Unit CRS
2102
mi
from 43215
Palo Alto, CA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
UCSD Antiviral Research Center CRS
1951
mi
from 43215
San Diego, CA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
UCSD Antiviral Research Center CRS
1951
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Ucsf Hiv/Aids Crs
2107
mi
from 43215
San Francisco, CA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Ucsf Hiv/Aids Crs
2107
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Harbor-UCLA CRS
1980
mi
from 43215
Torrance, CA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Harbor-UCLA CRS
1980
mi
from 43215
Torrance, CA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital CRS
1154
mi
from 43215
Aurora, CO
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital CRS
1154
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Denver Public Health CRS
1163
mi
from 43215
Denver, CO
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Denver Public Health CRS
1163
mi
from 43215
Denver, CO
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Yale University CRS
537
mi
from 43215
New Haven, CT
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Yale University CRS
537
mi
from 43215
New Haven, CT
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
VA Connecticut Healthcare System CRS
535
mi
from 43215
West Haven, CT
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
VA Connecticut Healthcare System CRS
535
mi
from 43215
West Haven, CT
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
AHF-The Kinder Medical Group CRS
993
mi
from 43215
Miami, FL
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
AHF-The Kinder Medical Group CRS
993
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
The University of Miami AIDS Clinical Research Unit (ACRU) CRS
992
mi
from 43215
Miami, FL
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
The University of Miami AIDS Clinical Research Unit (ACRU) CRS
992
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
AHF - South Beach CRS
993
mi
from 43215
Miami, FL
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
AHF - South Beach CRS
993
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Orlando Immunology Center CRS
794
mi
from 43215
Orlando, FL
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Orlando Immunology Center CRS
794
mi
from 43215
Orlando, FL
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Florida Department of Health - Hillsborough County
830
mi
from 43215
Tampa, FL
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Florida Department of Health - Hillsborough County
830
mi
from 43215
Tampa, FL
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
AIDS Research and Treatment Center of the Treasure Coast CRS
864
mi
from 43215
Vero Beach, FL
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
AIDS Research and Treatment Center of the Treasure Coast CRS
864
mi
from 43215
Vero Beach, FL
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
The Ponce de Leon Ctr. CRS
434
mi
from 43215
Atlanta, GA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
The Ponce de Leon Ctr. CRS
434
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Northwestern University CRS
274
mi
from 43215
Chicago, IL
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Northwestern University CRS
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Rush University CRS
277
mi
from 43215
Chicago, IL
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Rush University CRS
277
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
UIC Project WISH CRS
277
mi
from 43215
Chicago, IL
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
UIC Project WISH CRS
277
mi
from 43215
Chicago, IL
Click here to add this to my saved trials